PharmaLive.com Launches New Drugs Outlook Report
NEWTOWN, Pa., March 18, 2009--Canon Communications Pharmaceutical Media Group, publisher of PharmaLive.com Special Reports, announces the launch of New Drugs Outlook.
Developed by the editors and data specialists of Med Ad News and Canon Communications, this new report focuses on prescription medicines filed for FDA approval along with an overview of drug approvals during the past two decades. “The new drugs that are awaiting approval for 2009 show promise. The impact that these new medicines will have on the pharmaceutical industry and allied companies is more critical than ever before,” says Andrew Humphreys, Managing Editor of Med Ad News Special Reports and Editor in Chief of Canon Communications’ Data Products Group.
The report is presented in three sections as follows:
Products Awaiting Approval
• Comprehensive chart of new medicines awaiting U.S. marketing clearance with:
- Intended indication
- Disease category
- Drug class
• Analysis of some of the most-anticipated products
New Medicines of 2008
• Detailed chart of products FDA-approved last year via a new drug application with:
- Approval date
• Profiles of every medicine
Drug Approvals Over Time
• A listing of the prescription products cleared for marketing by FDA since 1990
Learn more about this and other reports at: www.PharmaLive.com/SpecialReports. The data contained in PharmaLive Special Reports is provided by eKnowledgeBase, an online database of pharmaceutical and biotechnology companies, business information, and products.
About Canon Communications Pharmaceutical Media Group
A division of Canon Communications LLC, Canon Communications Pharmaceutical Media Group is a provider of business and marketing information to the $500 billion worldwide pharmaceutical industry. We publish well-established business magazines, including Med Ad News, R&D Directions, and Pharmaceutical and Medical Packaging News and the industry Websites PharmaLive.com and TherapeuticsDaily.com.
Contact: Hilary Peirce
Posted: March 2009
Recommended for you